Risk factors for cardiovascular disease in systemic lupus erythematosus

被引:398
|
作者
Svenungsson, E [1 ]
Jensen-Urstad, K
Heimbürger, M
Silveira, A
Hamsten, A
de Faire, U
Witztum, JL
Frostegård, J
机构
[1] Karolinska Hosp, Dept Rheumatol, S-17176 Stockholm, Sweden
[2] Karolinska Hosp, Ctr Mol Med, S-17176 Stockholm, Sweden
[3] Karolinska Hosp, Dept Clin Physiol, S-17176 Stockholm, Sweden
[4] Karolinska Hosp, Dept Cardiol, S-17176 Stockholm, Sweden
[5] Karolinska Hosp, King Gustaf V Res Inst, S-17176 Stockholm, Sweden
[6] Huddinge Univ Hosp, Dept Rheumatol, S-14186 Huddinge, Sweden
[7] Karolinska Inst, Karolinska Hosp, Dept Med, Cardiovasc Lab, S-10401 Stockholm, Sweden
[8] Karolinska Inst, Karolinska Hosp, Inst Environm Med, S-10401 Stockholm, Sweden
[9] Karolinska Inst, Karolinska Hosp, Div Cardiovasc Epidemiol, S-10401 Stockholm, Sweden
[10] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
关键词
cardiovascular diseases; risk factors; atherosclerosis; ultrasonics;
D O I
10.1161/hc4101.097518
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Cardiovascular disease (CVD) is overrepresented in patients with systemic lupus erythematosus (SLE). We determined the prevalence of traditional and nontraditional risk factors for CVD in SLE patients with and without CVD compared with controls. Methods and Results-Twenty-six women (aged 52 +/-8.2 years) with SLE and a history of CVD (SLE cases) were compared with 26 age-matched women with SLE but without manifest CVD (SLE controls) and 26 age-matched population-based control women (population controls). Common carotid intima-media thickness (IMT) was measured by B-mode ultrasound as a surrogate measure of atherosclerosis. SLE cases had increased IMT compared with SLE controls (P=0.03) and population controls (P=0.001), whereas IMT of SLE controls did not differ from population controls. SLE cases had raised plasma concentrations of circulating oxidized LDL (OxLDL; P=0.03), as measured by the monoclonal antibody EO6, and autoantibodies to epitopes of OxLDL (P <0.001); dyslipidemia with raised triglycerides (P<0.001) and lipoprotein(a) (P=0.002) and decreased HDL-cholesterol concentrations (P=0.03); raised a-l-antitrypsin (P=0.002), lupus anticoagulant (P=0.007), and homocysteine levels (P=0.03); more frequent osteoporosis (P=0.03); and a higher cumulative prednisolone dose (P=0.05) compared with SLE controls. Disease duration, smoking, blood pressure, body mass index, and diabetes mellitus did not differ significantly between the groups. Conclusions-A set of distinct CVD risk factors separate SLE cases from SLE controls and population controls. If confirmed in a prospective study, they could be used to identify SLE patients at high risk for CVD in order to optimize treatment.
引用
收藏
页码:1887 / 1893
页数:7
相关论文
共 50 条
  • [1] Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus
    Angelica Sinicato, Nailu
    da Silva Cardoso, Priscila Aparecida
    Appenzeller, Simone
    [J]. CURRENT CARDIOLOGY REVIEWS, 2013, 9 (01) : 15 - 19
  • [2] Cardiovascular risk factors in systemic lupus erythematosus
    Harzallah, Amel
    Hajji, Mariem
    Kaaroud, Hayet
    Ben Hamida, Fethi
    Ben Abdallah, Taieb
    [J]. PAN AFRICAN MEDICAL JOURNAL, 2015, 22
  • [3] A STUDY OF THE CARDIOVASCULAR DISEASE RISK FACTORS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Zotos, N.
    Gianniki, M.
    Tatsina, I.
    Papadopoulou, A.
    Mosheta, E.
    Fasouloglou, A.
    Georgiou, C.
    Katagis, G.
    Bougias, D.
    Mitsis, C.
    Briasoulis, C.
    Chrisostomou, E.
    Pournou, A.
    Tsifetaki, N.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S104 - S104
  • [4] Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors
    Zeller, Carlos Borelli
    Appenzeller, Simone
    [J]. CURRENT CARDIOLOGY REVIEWS, 2008, 4 (02) : 116 - 122
  • [5] Systemic lupus erythematosus: managing cardiovascular risk factors
    Rahman, Anisur
    [J]. LANCET RHEUMATOLOGY, 2024, 6 (07): : e415 - e416
  • [6] CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Camilo Diaz-Coronado, Juan
    Herrera-Uribe, Sebastian
    Hernandez, Deicy
    Betancur-Vasquez, Laura
    Lacouture-Fierro, Jorge
    Gonzalez-Hurtado, Daniel
    Gonzalez-Arango, Juanita
    Uribe-Arango, Laura
    Fernanda Saavedra-Chacon, Maria
    Monsalve-Yepes, Santiago
    Guerra-Zarama, Sebastian
    David Serna-Giraldo, Jose
    David Lopez-Lopez, Juan
    Barbosa-Arana, Julian
    Camila Soto-Osorio, Maria
    Pineda-Tamayo, Ricardo A.
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S38 - S38
  • [7] CARDIOVASCULAR RISK FACTORS IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH HYPERTENSION
    Baya, W.
    Anoun, J.
    Ben Hassine, I.
    Mzabi, A.
    Karmani, M.
    Ismail, F. Ben Fredj
    Rezgui, A.
    Kechrid, C. Laouani
    [J]. JOURNAL OF HYPERTENSION, 2019, 37 : E169 - E169
  • [8] CONTRIBUTION OF FRAMINGHAM RISK FACTORS TO CARDIOVASCULAR DISEASE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Bessant, R.
    Rahman, A.
    Heath, J.
    Isenberg, D. A.
    [J]. RHEUMATOLOGY, 2002, 41 : 108 - 108
  • [9] Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus
    Oliveira, Christopher B.
    Kaplan, Mariana J.
    [J]. SEMINARS IN IMMUNOPATHOLOGY, 2022, 44 (03) : 309 - 324
  • [10] Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus
    Christopher B. Oliveira
    Mariana J. Kaplan
    [J]. Seminars in Immunopathology, 2022, 44 : 309 - 324